NCT02736266View on ClinicalTrials.gov

Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

174

Participants

Timeline

Start Date

February 27, 2017

Primary Completion Date

October 20, 2018

Study Completion Date

September 23, 2022

Conditions
Urothelial Bladder Carcinoma
Interventions
DRUG

Pembrolizumab (MK-3475)

Pembrolizumab given intravenously in 30 min. infusion every 3 weeks

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT02736266 - Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma | Biotech Hunter | Biotech Hunter